T-CURX Acquires Pantherna Therapeutics to Boost Clinical Validation of In-Vivo CAR-T Therapies

Why This Matters: Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

T-CURX signed a definitive agreement to acquire Pantherna Therapeutics, with an eye toward advancing chimeric antigen receptor T-cell (CAR-T) therapies. Both companies are based in Germany.

Pantherna, a biotechnology company, specializes in messenger RNA (mRNA) engineering and lipid nanoparticle (LNP) delivery technologies. It will continue to operate under the Pantherna Therapeutics name as a wholly owned subsidiary of T-CURX.

Companies Share Expertise

Both companies will leverage their complementary areas of expertise to accelerate clinical translation of CAR-T strategies. More specifically, the partnership will clearly focus on clinical validation of in-vivo CAR-T therapies.

The companies say their unification makes T-CURX the first European biotech with proprietary CAR-T and LNP technologies under one roof. Adding to that, they say the transaction allows for integration of key capabilities across the full value chain. This means from discovery to clinical development of CAR-T products.

Collectively, T-CURX and Pantherna have a current portfolio of 16 patent families protecting combined technologies and assets.

“With this acquisition, we are bringing together two highly complementary technology platforms and teams,” Ulf Grawunder, T-CURX Co-Founder/CEO, said. “We are taking a decisive step forward to accelerate the clinical development of differentiated, next-generation in-vivo CAR-T therapies.”

All About Accelerating CAR-T

Grawunder said in-vivo CAR-T assets in cancer would be expedited in their clinical development, but other indications apply as well.

“Joining T-CURX is a natural evolution of our collaboration,” Ansgar Santel, Pantherna Therapeutics CEO, said. “This integration allows us to address both stable and transient cell engineering strategies based on powerful and proven proprietary platforms. We believe this positions us uniquely to efficiently drive CAR-T innovation forward for patients in need.”

Financially, T-CURX is backed by private investors, plus an international syndicate of blue-chip biotech investors. T-CURX closed a $20.5 million (USD) Series A financing round at the end of 2025.

Private investors that had supported Pantherna will become new shareholders of T-CURX.